Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

BACKGROUND: Arterial stiffness is emerging as an independent risk factor for the development of chronic kidney disease. The sodium glucose co-transporter 2 (SGLT2) inhibitors, which lower serum glucose by inhibiting SGLT2-mediated glucose reabsorption in renal proximal tubules, have shown promise in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Aroor, Annayya R., Das, Nitin A., Carpenter, Andrea J., Habibi, Javad, Jia, Guanghong, Ramirez-Perez, Francisco I., Martinez-Lemus, Luis, Manrique-Acevedo, Camila M., Hayden, Melvin R., Duta, Cornel, Nistala, Ravi, Mayoux, Eric, Padilla, Jaume, Chandrasekar, Bysani, DeMarco, Vincent G.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6065158/
https://ncbi.nlm.nih.gov/pubmed/30060748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-018-0750-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars